TPST · Tempest Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Woiwode Thomas Director | ▲ Buy | Open Market | 2,118,644 Shares held | 4/29/2022 | View profile |
| Matthew Angel CEO and President | ▲ Buy | Open Market | 231,482 Shares held | 3/24/2026 | View profile |
| Versant Venture Capital VI, L.P. 10% Owner | ▼ Sell | Open Market | 209,941 Shares held | 8/12/2024 | View profile |
| Dubensky Thomas W. President | ▲ Buy | Open Market | 113,343 Shares held | 1/7/2022 | View profile |
| Stephen R. Brady President and CEO | ▲ Buy | Open Market | 46,376 Shares held | 7/3/2024 | View profile |
| Justin Trojanowski Corporate Controller | ▲ Buy | Open Market | 22,168 Shares held | 6/28/2024 | View profile |
| Samuel Whiting Chief Medical Officer | ▲ Buy | Open Market | 9,573 Shares held | 7/2/2024 | View profile |
Transaction History
| Matthew Angel | ▲ Buy | Open Market | 231,482 | $500K | 3/24/2026 |
| Matthew Angel | ▲ Buy | Open Market | 231,482 | $500K | 3/24/2026 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 387,999 | $427K | 8/12/2024 |
| Versant Venture Capital VI, L.P. | ▼ Sell | Open Market | 400,000 | $540K | 8/8/2024 |
| Stephen R. Brady | ▲ Buy | Open Market | 35,000 | $74K | 7/3/2024 |
| Samuel Whiting | ▲ Buy | Open Market | 4,672 | $10K | 7/2/2024 |
| Justin Trojanowski | ▲ Buy | Open Market | 7,500 | $16K | 6/28/2024 |
| Woiwode Thomas | ▲ Buy | Open Market | 2,118,644 | $5.0M | 4/29/2022 |
| Dubensky Thomas W. | ▲ Buy | Open Market | 2,000 | $10K | 1/7/2022 |
| Samuel Whiting | ▲ Buy | Open Market | 1,700 | $8K | 1/6/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
TPST Files Prospectus to Register Resale of Up to 9.5M Shares
Tempest Therapeutics has filed a prospectus to register the resale of up to 9,534,164 shares of common stock. This filing allows the company to offer more shares to the public, potentially increasing the available supply. The move is a routine corporate action that may influence the stock’s liquidity and market perception.
TPST Files Prospectus to Register Resale of Up to 9.5M Shares. Tempest Therapeutics has filed a prospectus to register the resale of up to 9,534,164 shares of common stock. This filing allows the company to offer more shares to the public, potentially increasing the available supply. The move is a routine corporate action that may influence the stock’s liquidity and market perception.